Short answer
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal quarter ended July 31, 2026 results announced September 14, 2026.
KESTRA MEDICAL TECHNOLOGIES, LTD. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter ended July 31, 2026 results announced September 14, 2026
- Financial details furnished in Exhibit 99.1, requiring review for revenue, earnings, and guidance impacts
Item EX-99.1 · Exhibit EX-99.1
- F1Q27 revenue $31.0M, up 60% year over year, driven by WCD market expansion, share gains, and improved payer mix
- Gross margin expanded to 56.5% from 45.7%, signaling meaningful volume leverage and cost-improvement benefits
- FY27 revenue guidance raised to $141M from $137M, implying 48% growth versus FY26
- GAAP net loss widened to $44.1M from $25.8M, including a $6.3M debt extinguishment loss
- Liquidity totaled $244.7M, or approximately $320M including committed unused term-loan availability, against $72.5M long-term debt
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other KESTRA MEDICAL TECHNOLOGIES, LTD. 8-K filings
Get the next KMTS 8-K as it lands
Follow KMTS for push alerts, or ask the research agent what this filing means.